Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.93 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257780 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL789234 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL12958834 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9173411 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL6938649 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9173436 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5737339 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9166176 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL21710733 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7070428 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | claimed |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-30 | — | — | US | claimed |
| WO-2017192553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | claimed |
| US-20160338947-A1 | DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG, WHILE PRESERVING PUPILLARY FUNCTION AND ACCOMMODATION | AMORPHEX THERAPEUTICS LLC | 2016-11-24 | — | — | US | claimed |
| WO-2016187426-A1 | A DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG | AMORPHEX THERAPEUTICS LLC (US) | 2016-11-24 | — | — | WO | claimed |
| US-20130224110-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2013-08-29 | — | — | US | claimed |
| EP-2616538-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | Cornell University (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037457-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2012-03-22 | — | — | WO | claimed |
| US-20110262442-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-6387889-B1 | REDUCING OCULAR TENSION | YAMASA CORPORATION (JP) | 2002-05-14 | — | — | US | claimed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| EP-1110554-A1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORPORATION (JP) | 2001-06-27 | — | — | EP | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0499185-B1 | Stable solid 2-octynyl adenosine and process for producing the same | YAMASA SHOYU KK (JP) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338947-A1 | DEVICE THAT DELIVERS A SUSTAINED LOW-DOSE OF A MYOPIA-SUPPRESSING DRUG, WHILE PRESERVING PUPILLARY FUNCTION AND ACCOMMODATION | MYOC, STRA6, MYOF | ADORA2A 735/4885ADORA2B 1684/4885ADORA3 1747/4885 |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | ADORA2A 7/4885ADORA2B 37/4885ADORA3 59/4885 |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | ADORA2A 7/4885ADORA2B 37/4885ADORA3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.